COGENTIX MEDICAL, INC. (NASDAQ:CGNT) Files An 8-K Results of Operations and Financial Condition

COGENTIX MEDICAL, INC. (NASDAQ:CGNT) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operations and Financial Condition

On July 18, 2017, Cogentix Medical, Inc. (the “Company”) announced it had entered into an exclusive license with Promepla, a Monaco-based medical device manufacturer, to launch an Endo-Urology product line in the U.S.

A press release announcing this transaction has been attached as Exhibit 99.1 to this Current Report, and for context, the press release contains the revenue growth rate for the Company’s urology products during the second quarter ended June 30, 2017. The Company expects to issue a more complete earnings release for the second quarter ended June 30, 2017 in early August.

The Company is furnishing the information contained in this Current Report, including Exhibit 99.1, to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

Exhibit Number



Press Release, dated July 18, 2017

EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Cogentix Medical Signs Agreement to Launch Endo-Urology Product Line in US; Launch to Further Increase Urology Products Growth Rate During 2018 MINNEAPOLIS,…
To view the full exhibit click here


Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

An ad to help with our costs